2nd clinical trials for promising Alzheimer's drug to take place at U of Sask.

During the first phase of clinical trials, 82 per cent of patients stabilized their cognitive functions within the first year of taking the drug while 54 per cent increased their cognitive functions.

Related Keywords

Saskatchewan ,Manitoba ,Canada ,Saskatoon ,Ron Geyer ,Joanne Bracken ,Garth Materie ,Alzheimer Society Of Sask ,Alzheimer Society Of Saskatchewan ,Health Canada ,University Of Saskatchewan ,Society Of Saskatchewan ,Afternoon Edition ,Saskatoon City Hospital ,Alzheimer Society ,